Provention Bio
United States
188 articles about Provention Bio
-
Provention Bio Reports First Quarter 2022 Financial Results and Provides Business Update
5/5/2022
Provention Bio, Inc. today reported financial results for the first quarter ended March 31, 2022, and provided a business update.
-
Provention Bio Announces the Grant of Inducement Awards - May 03, 2022
5/3/2022
Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced that the Company granted stock options to four new employees to purchase an aggregate of 110,000 shares of common stock.
-
Provention Bio to Report First Quarter 2022 Financial Results on May 5, 2022
4/28/2022
Provention Bio, Inc. today announced that it will report its first quarter 2022 financial results on Thursday, May 5, 2022, before the opening of the U.S. financial markets.
-
Provention Bio Announces the Grant of Inducement Awards - Apr 04, 2022
4/4/2022
Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced that the Company granted stock options to two new employees to purchase an aggregate of 195,000 shares of common stock.
-
It was a particularly busy week for clinical trial announcements. Let's take a look.
-
Provention Bio Announces Positive Final Results from First-In-Human Study of Coxsackievirus B Vaccine Candidate PRV-101
3/28/2022
Provention Bio, Inc. today announced positive results from the final analysis of its first-in-human PROVENT study of PRV-101, a polyvalent inactivated coxsackievirus B (CVB) vaccine candidate targeting all key CVB strains associated with type 1 diabetes (T1D) autoimmunity.
-
Provention Bio Announces FDA Acceptance of the Biologics License Application (BLA) Resubmission for Teplizumab for the Delay of Clinical Type 1 Diabetes in At-Risk Individuals
3/21/2022
Provention Bio, Inc. today announced that the resubmitted Biologics License Application (BLA) for teplizumab for the delay of clinical type 1 diabetes (T1D) in at-risk individuals has been considered a complete, class 2 response to the July 2021 action letter by the U.S. Food and Drug Administration (FDA).
-
Provention Bio has announced that the FDA has accepted its biologics license application resubmission for teplizumab, a drug intended to delay clinical Type I Diabetes (T1D) in at-risk individuals.
-
Provention Bio Announces the Grant of Inducement Awards - Mar 04, 2022
3/4/2022
Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced that the Company granted stock options to two new employees to purchase an aggregate of 55,000 shares of common stock.
-
Provention Bio to Present at Two Upcoming Virtual Investor Conferences in March 2022
3/3/2022
Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, announced that management will participate in two upcoming virtual investor conferences in March.
-
Provention Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
2/24/2022
Provention Bio, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided a business update.
-
Provention Bio Announces Biologics License Application (BLA) Resubmission for Teplizumab to Address Complete Response Letter (CRL)
2/22/2022
Provention Bio, Inc. today announced it has resubmitted the Biologics License Application (BLA) for teplizumab for the delay of clinical type 1 diabetes (T1D) in at-risk individuals.
-
Provention Bio to Report Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022
2/17/2022
Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its fourth quarter and full year 2021 financial results on Thursday, February 24, 2022, before the opening of the U.S. financial markets.
-
Provention Bio to Present at the Virtual SVB Leerink 11th Annual Global Healthcare Conference
2/10/2022
Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in a fireside chat presentation at the SVB Leerink 11th Annual Global Healthcare Conference.
-
Provention Bio Announces the Grant of Inducement Award
2/4/2022
Provention Bio, Inc. today announced that the Company granted stock options on February 1, 2022 to a new non-executive employee to purchase an aggregate of 30,000 shares of common stock.
-
The resubmission follows a Type B pre-BLA resubmission meeting with the US Food and Drug Administration (FDA).
-
Provention Bio Resubmitting Biologics License Application for Delay of Clinical Type 1 Diabetes in At-Risk Individuals Following Type B Meeting with the FDA
1/27/2022
Provention Bio, Inc. today announced its intent to resubmit the teplizumab Biologics License Application.
-
Provention Bio Announces Initiation of the Phase 2a PREVAIL-2 Study of PRV-3279 (CD32B × CD79 Bispecific DART® Molecule) in Systemic Lupus Erythematosus (SLE)
1/20/2022
Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the initiation of the Phase 2a PREVAIL-2 study (PRV-3279 EVAluation In Lupus- Phase 2).
-
Provention Bio Announces the Grant of Inducement Awards - Jan 07, 2022
1/7/2022
Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced that the Company granted stock options to Randy Anderson, Senior Vice President of Biometrics to purchase an aggregate of 130,000 shares of common stock.
-
Provention Bio to Present at the Virtual H.C. Wainwright BioConnect Conference
1/6/2022
Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, announced that management will present at the H.C. Wainwright BioConnect 2022 Conference, being held virtually January 10-13, 2022.